Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rothley

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Progress in Clinical and Biological Research|January 1, 1989
Cytotoxicity and metabolism of E-DES-diphosphateH Oelschläger, D Rothley, U Dunzendorfer
Arzneimittel-Forschung|August 1, 1986
[Plasma concentrations of fosfestrol as well as diethylstilbestrol on their conjugates following intravenous administration on prostatic carcinoma patients]H Oelschläger, D Rothley, U Dunzendorfer
Archiv Der Pharmazie|June 1, 1988
[Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)]H Oelschläger, D Rothley, W Schmidt
Journal of Pharmaceutical and Biomedical Analysis|February 1, 1994
Identification of drug glucuronides in human urine by RP-HPLC after derivatizationC Kohl, H Oelschläger, D Rothley
European Journal of Drug Metabolism and Pharmacokinetics|April 1, 1997
Interaction of chlormezanone with rat liver microsomes and its degradationW Klinger, H Oelschläger, E Karge, et al.
Archiv Der Pharmazie|April 1, 1994
[The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate]H Oelschläger, K H Hellwich, D Rothley
Archiv Der Pharmazie|November 1, 1992
[Pharmacokinetics of hypolipedemic agents. 9. The question of biliary excretion of the hypolipidemic agent ciprofibrate (1) (2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-2-methylpropionic acid]H Oelschläger, D Rothley, D Schröder, et al.
Archiv Der Pharmazie|October 1, 1989
[The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?]H Oelschläger, D Rothley, K H Hellwich, et al.
Arzneimittel-Forschung|January 1, 1980
[Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)]H Oelschläger, D Rothley, M Ewert, et al.
Archiv Der Pharmazie|August 1, 1991
[The pharmacokinetics of antilipemic agents. 8. Unequivocal characterization of ciprofibrate-O-beta-d-glucuronide]H Oelschläger, C Kohl, D W Armstrong, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Progress in Clinical and Biological Research|January 1, 1989
Cytotoxicity and metabolism of E-DES-diphosphateH Oelschläger, D Rothley, U Dunzendorfer
Arzneimittel-Forschung|August 1, 1986
[Plasma concentrations of fosfestrol as well as diethylstilbestrol on their conjugates following intravenous administration on prostatic carcinoma patients]H Oelschläger, D Rothley, U Dunzendorfer
Archiv Der Pharmazie|June 1, 1988
[Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)]H Oelschläger, D Rothley, W Schmidt
Journal of Pharmaceutical and Biomedical Analysis|February 1, 1994
Identification of drug glucuronides in human urine by RP-HPLC after derivatizationC Kohl, H Oelschläger, D Rothley
European Journal of Drug Metabolism and Pharmacokinetics|April 1, 1997
Interaction of chlormezanone with rat liver microsomes and its degradationW Klinger, H Oelschläger, E Karge, et al.
Archiv Der Pharmazie|April 1, 1994
[The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate]H Oelschläger, K H Hellwich, D Rothley
Archiv Der Pharmazie|November 1, 1992
[Pharmacokinetics of hypolipedemic agents. 9. The question of biliary excretion of the hypolipidemic agent ciprofibrate (1) (2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-2-methylpropionic acid]H Oelschläger, D Rothley, D Schröder, et al.
Archiv Der Pharmazie|October 1, 1989
[The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?]H Oelschläger, D Rothley, K H Hellwich, et al.
Arzneimittel-Forschung|January 1, 1980
[Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)]H Oelschläger, D Rothley, M Ewert, et al.
Archiv Der Pharmazie|August 1, 1991
[The pharmacokinetics of antilipemic agents. 8. Unequivocal characterization of ciprofibrate-O-beta-d-glucuronide]H Oelschläger, C Kohl, D W Armstrong, et al.
Pageof 3